Salute e Benessere

Navamedic ASA: National approvals of Flexilev® in OraFID® granted across all…

Flexilev® in OraFID® ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more frequent doses. Flexilev ®in OraFID ®ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more...
PR Newswire
13/08/2025

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability…

In the trial, 70 healthy adults received single dose of either a semaglutide microneedle patch or a subcutaneous injection. Plasma concentrations were measured and then compared with results from semaglutide subcutaneous injection under the same conditions. After adjusting to equivalent dose, the patch showed more than 80%relative bioavailability compared with injection. In the trial, 70 healthy adults received single dose of either a semaglutide microneedle patch or a subcutaneous injection...
PR Newswire
13/08/2025

Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030

The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large…
PR Newswire
13/08/2025

Oxehealth Rebrands as LIO, Launching Next-Gen Platform to Transform Inpatient…

Already trusted by half of NHS England's mental health providers through its predecessor, Oxevision, LIO brings together ambient monitoring, digital observations and management insights in a single, unified platform. This all-in-one approach supports both frontline teams and leaders, making it easier to provide safe, high-quality and efficient care across wards and services. Already trusted by half of NHS England's mental health providers through its predecessor, Oxevision, LIO brings…
PR Newswire
13/08/2025

Sectra's new security attestation lowers barrier for healthcare providers to…

Sectra One Cloud, which operates within the Microsoft Azure public cloud environment, now has both C5 and CSA STAR Level 2. While the CSA STAR Level 2 certificate, received in 2024, applies to global standards, the C5 attestation addresses requirements specific to the German market. Together, these certificates reflect Sectra's proactive leadership in advancing cloud security and transparency for the global healthcare market. Sectra One Cloud, which operates within the Microsoft Azure public...
PR Newswire
13/08/2025

Implantica finishes new multi-cavity production tool for RefluxStop® to support…

This crucial milestone comes after years of careful planning and rigorous development, representing Implantica's deepening roots in the United States and commitment to serving future customers across the U.S. and the rest of the world. This crucial milestone comes after years of careful planning and rigorous development, representing Implantica's deepening roots inthe United Statesand commitment to serving future customers across the U.S. and the rest of the world. Dr. Peter Forsell,...
PR Newswire
13/08/2025

Greywolf Therapeutics begins dosing of the first treatment to target the…

This is the first ever autoimmunity study to evaluate a potential functional cure that targets the antigenic source – the origin of autoimmune diseaseThe Phase 1/2 study (up to 141 participants) will evaluate the safety, tolerability and efficacy of GRWD0715 in healthy volunteers and participants with axial spondyloarthritis (axSpA) GRWD0715 is an investigational small molecule designed to interrupt T-cell activation by inhibiting the peptide processing enzyme ERAP1 (Endoplasmic Reticulum...
Nasdaq GlobeNewswire
13/08/2025

Santhera Secures Agreement with GEN for the Distribution of AGAMREE®…

Pratteln, Switzerland , 13 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Supply and sales by GEN are expected to start in the first half of 2026, initially on a named patient basis, followed by commercial sales...
Nasdaq GlobeNewswire
13/08/2025

Global Digital Health Market Poised for Robust Growth at a CAGR of ~18% by 2032…

Digital Health Overview Digital Health Overview Digital health refers to the use of technology to improve health outcomes, enhance healthcare delivery, and empower patients in managing their well-being. It encompasses a broad range of tools and services, including telemedicine, mobile health apps, wearable devices, electronic health records (EHRs), and artificial intelligence. These innovations are transforming traditional healthcare systems by making care more accessible, personalized,...
PR Newswire
12/08/2025

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding…

Key Takeaways from the Tumor-Infiltrating Lymphocyte Therapies Market Report Key Takeaways from the Tumor-Infiltrating Lymphocyte Therapies Market Report Discover which indication is expected to grab the major tumor-infiltrating lymphocyte therapies market share @Tumor-Infiltrating Lymphocyte Therapies Market Report Tumor-Infiltrating Lymphocyte Therapies Market Dynamics The tumor-infiltrating lymphocyte therapies market is poised for transformative growth, driven by...
PR Newswire
12/08/2025

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 12, 2025 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:2,580 shares at DKK 1,025.00, 1,874 shares at DKK 1,050.00, and 109 shares at DKK 1,161.00...
Nasdaq GlobeNewswire
12/08/2025

TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”

Allschwil, Switzerland – August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has nominated TRYVIO™ (aprocitentan) in the category of “Best Pharmaceutical Product” in the 2025 Prix Galien USA awards. The winner will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025.To qualify for the Prix Galien Award, each candidate must be US Food and Drug...
Nasdaq GlobeNewswire
12/08/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025

Aggregated presentation by day and by market Statement of transactions in own shares from August 4th to August 8th 2025 Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1104/08/2025FR0010259150 2 000 ...
Nasdaq GlobeNewswire
12/08/2025

Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction

Accenture projects AI could unlock $461 billion in healthcare value by 2035, but success requires platforms that deliver reliable results in critical diagnostics where mistakes prove dangerous. Several innovators are developing advanced systems to capture this opportunity across patient screening and drug discovery. Accenture projects AI couldunlock$461 billion in healthcare value by 2035, but success requires platforms thatdeliver reliable resultsin critical diagnostics where...
PR Newswire
12/08/2025

Mice Model Market worth US$2.74 billion in 2030 with 10.0% CAGR |…

Browse in-depth TOC on "Mice Model Market" Browse in-depth TOC on "Mice Model Market" 576 - Tables 54 - Figures 446 - Pages By model type,the market is categorized by model type into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. In 2024, the inbred mice segment accounted for the largest share of the market. Inbred mice are developed through at least 20 generations of sibling or parent–offspring matings, producing genetically identical...
PR Newswire
12/08/2025

Hearing Aids Market worth US$14.42 billion by 2030 with 6.8% CAGR |…

Browse in-depth TOC on "Hearing Aids Market" Browse in-depth TOC on "Hearing Aids Market" 331 - Tables 49 - Figures 293 - Pages By type,the hearing aids market is categorized based on the type of hearing loss, specifically into sensorineural and conductive hearing loss. In 2024, sensorineural hearing loss captured the largest market share due to its significant prevalence, particularly among the geriatric population, and the consistent availability of effective treatment...
PR Newswire
12/08/2025

Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury…

Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has commenced purchases of Ethereum (ETH), advancing its digital asset treasury reserve strategy.Pursuant to its financing facility of up to $300 million (the “Facility”) with a U.S.-based institutional investor, Cosmos Health has completed its initial $1 million purchase of ETH. Greg Siokas, CEO of Cosmos Health,...
Nasdaq GlobeNewswire
12/08/2025

IBS and IBD Treatment Market to Show Strong Growth | BCC Research LLC

The report provides a detailed analysis of the global market for therapeutics targeting irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). It segments the market by disease type, symptom type, and drug class. IBS therapeutics are categorized into IBS with constipation, diarrhea, and mixed symptoms, with treatments including guanylate cyclase-C agonists, antibiotics, laxatives, and antispasmodics. IBD therapeutics are divided into ulcerative colitis and Crohn's disease, with…
PR Newswire
12/08/2025

Zifo on AI in Biopharma: Not a Magic Wand, But a Transformative Tool

Sujeegar Jeevanandam, who goes by his nickname SJ, is the Principal Consultant for Data and AI at Zifo, with over 15 years of experience in R&D scientific informatics. Sujeegar Jeevanandam, who goes by his nickname SJ, is the Principal Consultant for Data and AI at Zifo, with over 15 years of experience in R&D scientific informatics. AI, Sujeegar explains, is less about sudden, headline-grabbing breakthroughs and more about targeted, cumulative value: "If you can even create a 5%…
PR Newswire
12/08/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated...
Nasdaq GlobeNewswire
12/08/2025

Airway Therapeutics Receives European Medicines Agency Pediatric Committee…

"We are pleased to have reached agreement with the PDCO on the Pediatric Investigation Plan and pivotal study design for zelpultide alfa, a ground-breaking therapy being developed to prevent BPD in very preterm infants, a highly vulnerable population with no approved preventative treatments," said Dr. Marc Salzberg, Chairman, Chief Executive & Medical Officer of Airway Therapeutics. "This marks a significant milestone in advancing a potential first-in-class preventive therapy…
PR Newswire
12/08/2025

"Prime Time," a Branded Peyronie's Disease Commercial for XIAFLEX® (collagenase…

"We're proud to continue our strong commitment to men's health and speak directly to men who may be worried about their Peyronie's disease symptoms," said Justin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. "With this campaign, we're urging men to speak with a urology specialist and explore whether XIAFLEX is right for them, while sharing information about common hesitations or misconceptions that might be holding them back." "We're…
PR Newswire
12/08/2025

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for…

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected in all three indications this year with first-in-class potential in NT2 and IH ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders underway with...
Nasdaq GlobeNewswire
12/08/2025

AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the…

“We are thrilled that the FDA has granted Fast Track Designation for AAVB-039, as it underscores the urgent unmet need and important potential of our program due to the serious nature of challenges faced by patients living with Stargardt disease,” said Dr. Natalia Misciattelli, Chief Executive Officer of AAVantgarde. “This designation represents an important milestone for our program and enables us to accelerate development efforts as we work to bring a potentially transformative therapy to...
Nasdaq GlobeNewswire
12/08/2025
Altri  Comunicati